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ABSTRACT
Objective: To assess whether the obesity paradox
persists in the long term and to study the effect of
optimal medical treatment on this phenomenon.
Design: A retrospective cohort study.
Setting: A tertiary care centre in Rotterdam.
Participants: From January 2000 to December 2005,
6332 patients undergoing percutaneous coronary
intervention for coronary artery disease were
categorised into underweight (body mass index
(BMI)<18.5), normal (18.5e24.9), overweight
(25e29.9) and obese (>30).
Primary outcome measure: Mortality.
Secondary outcome measures: Cardiac death and
non-fatal myocardial infarction.
Results: Optimal medical treatment was more
common in obese patients as compared with normal
weight patients (85% vs 76%; p<0.001). At a mean of
6.1 years, overweight and obese patients had a lower
risk of all-cause mortality (HR: 0.75, 95% CI 0.66 to
0.86 and HR: 0.72, 95% CI 0.60 to 0.87, respectively).
After adjusting for OMT in the multivariate analysis,
BMI did not remain an independent predictor of long-
term mortality (HR: 0.90, 95% CI 0.72 to 1.12 and HR:
1.07, 95% CI: 0.80 to 1.43, respectively).
Conclusion: BMI is inversely related to long-term
mortality in patients treated with percutaneous
coronary intervention. Patients with a normal BMI are
on suboptimal medical treatment when compared with
those with a high BMI. A more optimal medical
treatment in the obese group may explain the observed
improved outcome in these patients.
The increasing incidence of obesity in the
industrialised world is a major public health
concern. An increased body mass index
(BMI) is associated with a higher mortality
rate in the general population, and obesity is
also well known as an independent risk factor
for the development of cardiovascular
disease.1 2 However, several studies have
shown that cardiovascular patients who are
overweight or obese have a better outcome
than patients with a normal weight.3 4
Indeed, the greatest mortality rates are
observed in patients with a very low BMI
(<18.5 kg/m2) and this phenomenon has
been termed the ‘obesity paradox’.3e5
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ARTICLE SUMMARY
Article focus
- Whether the obesity paradox persists in the long
term.
- The effect of optimal medical treatment (OMT) on
this phenomenon.
Key messages
- Body mass index (BMI) is inversely related to
long-term mortality in patients treated with
percutaneous coronary intervention.
- Patients with a normal BMI are on suboptimal
medical treatment when compared with those
with a high BMI.
- A more optimal medical treatment in the obese
group may explain the observed improved
outcome in these patients.
Strengths and limitations of this study
- Strengths of this study are that we examine the
long-term effects of BMI on outcome and we try
to explore the mechanisms of the obesity
paradox. Limitations of the study are that we
cannot prove the mechanism with an observa-
tional study and that details about OMT, such as
duration of therapy and medication adherence,
are lacking.
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Most studies examining the role of BMI on mortality in
patients treated with percutaneous coronary interven-
tion (PCI) have focused on the short-term effects,6e10
while only a few studies examined the impact of BMI on
long-term mortality.11e14 While many studies have
examined the obesity paradox, only a few studies
explored the mechanisms of this phenomenon.4 15 16 A
more aggressive lifestyle modification and optimisation
of medical treatment may be a plausible reason for the
enhanced survival in individuals who are obese at the
time of coronary revascularisation.
Hence, the aims of this study were (1) to evaluate the
effect of BMI on long-term mortality in a consecutive
series of patients treated with PCI and (2) to determine
whether a difference in the use of optimal medication at
follow-up between the different BMI groups is
a contributing factor for the obesity paradox.
METHODS
Study population
Between 1 January 2000 and 31 December 2005, a total
of 7217 PCI’s were performed in our institution. Bare
metal stents were used exclusively in 2681 PCI’s
performed between January 2000 and 15 April 2002.
Subsequently, 1035 interventions were performed
between 16 April 2002 and 23 February 2003, using
sirolimus-eluting stents (Cypher; Cordis Corp.,
Johnson & Johnson, Warren, New Jersey, USA), as part of
RESEARCH registry.17 The following 3339 interventions
from 23 February 2003 to 31 December 2005 were
performed using paclitaxel-eluting stents (TAXUS
Express2 or Liberte´; Boston Scientific, Natick, Massa-
chusetts, USA), as part of the T-SEARCH registry.18 Only
patients (n¼6332) with registered baseline weight and
height were eligible for inclusion in the current study.
The study was performed in line with ethical guidelines
in accordance with the Declaration of Helsinki.
Baseline data
Demographic variables included gender, age, height and
weight. Information on clinical variables (ie, dyslipi-
daemia, hypertension, smoking, diabetes mellitus, family
history of coronary artery disease (CAD), indication for
PCI, previous myocardial infarction (MI), previous
coronary artery bypass graft surgery, previous PCI,
multivessel disease and left ventricular ejection fraction
(LVEF)) were prospectively collected at the time of the
procedure and recorded in the institutional database.
Dyslipidaemia was defined as total cholesterol levels
$240 mg/dl (6.21 mmol/l) or if the patient was on
lipid-lowering medication. Hypertension was defined as
blood pressure >140/90 mm Hg or if a patient was
being treated with antihypertensive drugs. Diabetes
mellitus was defined in patients being treated by oral
antiglycaemic agents or insulin.
Body mass index
BMI was defined as weight in kilograms divided by the
square of the height in metres. In our institution, height
and weight are self-reported unless the patient does not
know in which case this is performed in the referral
clinic. Categorisation of BMI was adopted from WHO
and the National Institutes of Health19 and defined as
underweight (BMI <18.5 kg/m2), normal weight
(18.5e24.9 kg/m2), overweight (25e29.9 kg/m2) and
obese ($30 kg/m2).
Outcome
End points were all-cause mortality, cardiac death and
non-fatal MI, and major cardiac events (a composite of
cardiac death or non-fatal MI). Cardiac death was
defined as death from any cardiac cause including
sudden cardiac death, MI, congestive heart failure,
cardiac arrhythmias and death in which there is evidence
of a primary cardiac cause that could not be classified as
mentioned above. Sudden cardiac death was defined as
unexpected natural death due to cardiac causes within
1 h of onset of acute symptoms. Criteria of MI diagnosis
included two or more of the following: (1) typical chest
pain lasting for more than 20 min, (2) development of
typical electrocardiographic changes (new Q waves
>1 mm or >30 ms in two contiguous ECG leads), (3)
elevated levels of serum markers for cardiac necrosis
(creatine kinase (CK) >2 or CK-MB level >3 times the
upper limit of normal).
Information about the in-hospital outcome was
obtained from an electronic clinical database main-
tained at our institution and by review of the hospital
records for those transferred to other hospitals. In-
hospital outcomes are included in the 6-year outcome.
Post-discharge survival status was obtained from the
Municipal Civil Registries. Questionnaires with infor-
mation about anginal status, repeated hospital admis-
sions, revascularisation procedures and medication use
were sent to all living patients on a yearly basis. The
hospital records, referring physicians and institutions
were consulted for additional information whenever
necessary. Events were adjudicated by two independent
cardiologists according to criteria defined above.
Optimal medical treatment
We defined optimal medication as the use of three or
more (since some of the patients may be intolerant to
one of the medications) of the four types of medication
(aspirin, b blockers, statins, ACE inhibitors/angiotensin
II receptor blockers) known to improve prognosis in
patients with CAD according to ACC/AHA guidelines.20
Statistical analysis
Categorical variables were compared with the c2 test and
continuous variables with analysis of variance. Univari-
able and multivariable Cox proportional hazard regres-
sion analyses were used to examine the relation between
BMI and the defined end points. All BMI classes were
entered into the model, with normal weight patients
(BMI 18.5e24.9 kg/m2) as the reference. Multivariable
analysis was adjusted for all baseline characteristics,
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which were available for all patients included in the
study. Optimal medical treatment was added to the
model to assess its importance as an independent
predictor. KaplaneMeier curves were generated to
graphically present the time to death for patients in the
different BMI groups. Additionally univariate and
multivariate Cox regression analysis was performed with
BMI as a continuous variable to determine the relation of
an increase in 1 kg/m2 and the primary end point. The
effect of the introduction of optimal medical treatment
(OMT) on the model was tested as in the models with
BMI as a categorical variable. Landmark Cox regression
analysis at 2-year follow-up was performed to assess for
changes in predictors of the end point mortality and to
determine the effect of OMT on late outcome.
Patients lost to follow-up were considered at risk until
the day of final contact, at which point they were
censored. The log-rank test was used to ascertain
whether differences between groups were statistically
significant. All tests were two tailed and a probability
value of <0.05 was considered statistically significant. For
Cox proportional hazard regression analyses, HRs and
their corresponding 95% CIs were reported. All data
were analysed using SPSS V.17.0 for Windows (SPSS
Inc.).
RESULTS
Follow-up on survival status was available for 98% of
patients. The average follow-up time was 6.1 years (range
3e11 years). In total, there were 1059 deaths (17%) of
which 454 (43%) were cardiac.
The small size (n¼35) of the underweight group
precludes any reliable analyses and the group was
therefore excluded. Patient baseline characteristics and
clinical data according to the three BMI categories are
shown in table 1. Obese patients tended to be younger,
and although the overall population was predominantly
comprised of men, gender was more equally represented
in the obese group. Dyslipidaemia, hypertension and
diabetes mellitus were more common in the obese
group, while current smoking was more prevalent in the
normal weight group.
The different types of medication used at follow-up
according to the three BMI categories are shown in table
2. Obese patients tended to use more b blockers and
ACE inhibitors compared with the normal weight group
resulting in more optimal medical treatment at follow-up
in the obese group.
Univariate and multivariate associations between BMI
and long-term outcome are presented in table 3. Clinical
characteristics that had a significant association on
multivariate analysis were age, gender, diabetes mellitus,
multivessel disease and LVEF. In univariate analyses,
overweight and obese patients had more favourable
long-term outcomes in terms of all-cause death (HR:
0.72, 95% CI 0.63 to 0.82 and HR: 0.61, 95% CI 0.51 to
0.74, respectively) and cardiac death (HR: 0.77, 95% CI
0.63 to 0.94 and HR: 0.73, 95% CI 0.56 to 0.95,
Table 1 Baseline characteristics
Variable
BMI (kg/m2)
Total (n[6297)
18.5e24.9
(n[2095)
25e29.9
(n[2956) >30 (n[1246) p Value
Male, n (%) 4562 (72) 1466 (70) 2266 (77) 830 (67) <0.001
Age 6 SD 61611.4 62612.2 62611.2 59610.4 <0.001
BMI 6 SD 27.064.0 23.1161.5 27.2361.4 33.063.1 <0.001
Cardiovascular history, n (%)
Previous MI 2128 (34) 686 (33) 1011 (34) 431 (35) 0.448
Previous CABG 692 (11) 200 (10) 354 (12) 138 (11) 0.025
Previous PCI 1630 (26) 513 (25) 764 (26) 353 (28) 0.049
Multivessel disease 3437 (55) 1122 (54) 1635 (55) 680 (55) 0.47
Risk factors, n (%)
Dyslipidaemia 4759 (76) 1531 (73) 2246 (76) 982 (79) 0.001
Hypertension 2554 (41) 714 (34) 1161 (39) 679 (55) <0.001
Family history 1921 (31) 623 (30) 895 (30) 403 (32) 0.27
Current smoker 1512 (24) 561 (27) 661 (22) 290 (23) 0.001
Diabetes mellitus 1057 (17) 251 (12) 466 (16) 340 (27) <0.001
Indication for PCI, n (%) 0.006
Stable angina 3059 (49) 965 (46) 1450 (49) 644 (52)
Unstable angina 2084 (33) 707 (34) 971 (33) 406 (33)
Acute MI 1154 (18) 423 (20) 535 (18) 196 (16)
LVEF*, n (%) 0.603
Good 3052/3763 (81) 1013/1266 (80) 1442/1757 (82) 597/740 (81)
Impaired 711/3763 (19) 253/1266 (20) 315/1757 (18) 143/740 (19)
*Data for this characteristic were not available in all patients.
BMI, body mass index; CABG, coronary bypass graft surgery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI,
percutaneous coronary intervention.
Schenkeveld L, Magro M, Oemrawsingh RM, et al. BMJ Open 2012;2:e000535. doi:10.1136/bmjopen-2011-000535 3
Optimal medical treatment and the obesity paradox
group.bmj.com on June 16, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
respectively). (table 3, figure 1) Overweight patients also
showed a lower risk for the composite end point of
cardiac death and non-fatal MI (HR: 0.84, 95% CI 0.71
to 0.99). Most of these differences remained significant
after multivariate adjustments for all baseline character-
istics. However, the lower incidence of cardiac death in
obese patients did not remain significant after multi-
variate analysis. Moreover, when adjusting for baseline
characteristics and optimal medication at follow-up,
overweight and obese patients had a equal long-term
survival (HR: 0.90, 95% CI 0.72 to 1.12 and HR: 1.07,
95% CI 0.80 to 1.43, respectively) compared with the
normal weight group.
In a model with BMI as a continuous variable, one unit
increase in BMI showed HR 0.95 (95% CI 0.93 to 0.97),
p<0.001, adjusted HR 0.96 (95% CI 0.95 to 0.98),
p<0.001. When OMT was introduced in the model, the
relation did not remain significant: HR 1.00 (95% CI
0.98 to 1.03), p¼0.81.
For the whole population, OMT had HR 0.63, for the
normal population 0.60, for the overweight 0.64 and for
the obese 0.69.
In a landmark analysis at 2 years, multivariate predictors
of late outcome included gender, BMI, age, hypercho-
lesterolaemia, diabetes mellitus, family history of CAD,
previous coronary artery bypass graft surgery and LVEF.
The introduction of OMT in the 2-year landmark Cox
regression model also altered the significance of BMI
from overweight versus normal (HR: 0.806, 95% CI 0.678
to 0.960, p¼0.015) and obese versus normal (HR: 0.840,
95% CI 0.661 to 1.067, p¼0.152) in the model without
OMT to overweight versus normal (HR: 0.911, 95% CI
0.722 to 1.149, p¼0.429) and obese versus normal (HR:
1.122, 95% CI 0.819 to 1.537, p¼0.472) in the model
with OMT.
The individual medications were analysed in a separate
Cox regression model and statin use showed the stron-
gest independent protective effect on long-term
mortality, statins HR 0.60 (95% CI 0.46 to 0.78),
p<0.0001. All the other three medications also showed
independent protective effect as follows: aspirin HR 0.75
(95% CI 0.60 to 0.95), p¼0.014, b blocker HR 0.83 (95%
CI 0.66 to 1.04), p¼0.109, and ACE inhibitors HR 0.84
(95% CI 0.69 to 1.03), p¼0.093.
DISCUSSION
This study confirms the validity of the ‘obesity paradox’
with an inverse relation in all-cause mortality and BMI of
Table 2 Medication at follow-up
Variable
BMI (kg/m2)
Total
(n[6297)
18.5e24.9
(n[2095)
25e29.9
(n[2956)
>30
(n[1246) p Value
Medication, n (%)
Aspirin 5352 (85) 1366 (85) 2014 (85) 825 (86) 0.979
b blocker 5038 (80) 1246 (78) 1883 (80) 832 (86) <0.001
Statin 5793 (92) 1451 (91) 2163 (92) 898 (93) 0.092
ACE inhibitor 3149 (50) 775 (48) 1154 (49) 547 (57) <0.001
Optimal medication*, n (%) 4975 (79) 1219 (76) 1839 (78) 818 (85) <0.001
*Defined as the use of three or more of the four types of medication.
BMI, body mass index.
Table 3 HRs of study end points
Events
Univariate Multivariate* Multivariatey
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
All-cause mortality
Overweight 456 (15%) 0.72 (0.63 to 0.82) <0.001 0.75 (0.66 to 0.86) <0.001 0.90 (0.72 to 1.12) 0.335
Obese 159 (13%) 0.61 (0.51 to 0.74) <0.001 0.72 (0.60 to 0.87) 0.001 1.07 (0.80 to 1.43) 0.663
Cardiac death
Overweight 198 (7%) 0.77 (0.63 to 0.94) 0.011 0.81 (0.66 to 0.99) 0.044 1.05 (0.71 to 1.57) 0.800
Obese 77 (6%) 0.73 (0.56 to 0.95) 0.019 0.82 (0.62 to 1.08) 0.152 1.02 (0.60 to 1.75) 0.939
Non-fatal MI
Overweight 138 (5%) 0.81 (0.63 to 1.04) 0.095 0.79 (0.61 to 1.01) 0.056 0.75 (0.57 to 0.98) 0.036
Obese 79 (6%) 1.12 (0.84 to 1.49) 0.434 1.03 (0.77 to 1.38) 0.844 0.88 (0.63 to 1.24) 0.472
Cardiac death or non-fatal MI
Overweight 336 (13%) 0.84 (0.71 to 0.99) 0.038 0.83 (0.70 to 0.99) 0.033 0.95 (0.74 to 1.21) 0.658
Obese 156 (15%) 0.87 (0.70 to 1.07) 0.186 0.87 (0.69 to 1.08) 0.202 0.94 (0.68 to 1.30) 0.722
*Adjusted for all baseline characteristics.
yAdjusted for all baseline characteristics and optimal medication.
MI, myocardial infarction.
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patients undergoing percutaneous revascularisation in
the long term up to 6 years. Patients with higher BMI at
baseline have more optimal medical treatment, which
may explain the reduction in mortality as observed in
these patients up to this time point.
In the current study, we found that the inverse relation
between BMI and mortality persists during long-term
follow-up of patients treated with PCI. The overweight
and obese groups showed almost 30% lower mortality
than patients with a normal BMI.
In this population, crude death rate was 17% during
a mean follow-up of 6 years. Cardiac deaths were
responsible for 43% of all deaths. As expected, comorbid
conditions (eg, dyslipidaemia, hypertension and dia-
betes mellitus) were more prominent in the obese
population.
Several other studies have shown a paradoxical effect
of moderate obesity on outcome after PCI.6e12 They also
found significantly worse outcomes in patients with
a BMI >30 or <20 kg/m2. These results were echoed in
a large meta-analysis by Romero-Corral et al21 who
included studies with a total of 250 152 patients under-
going PCI or coronary artery bypass grafting. In fact,
overweight and obese patients with coronary heart
disease had a lower risk for total and cardiovascular
mortality compared with underweight and normal
weight patients with coronary heart disease. Our study
results are in line with these findings; however, while the
duration of the follow-up period in most of these studies
was restricted to 1 year, that period was extended to
6 years in the current study.
The reason for the paradoxic U- or J-shaped relation
between BMI and adverse outcome is not yet under-
stood. Several explanations for this phenomenon have
been suggested. Peripheral adiposity confers cardiovas-
cular benefits due to the secretion of adiponectin, which
has anti-inflammatory, insulin-sensitising and anti-
atherogenic effects. Also, these patients seem to have
a lower total body fat content, which implies that
subcutaneous body fat is relatively ‘inert’ in metabolic
and inflammatory/mediation terms.22 Furthermore, it
has been suggested that hypercholesterolaemia and high
levels of serum low-density lipoproteins associated with
obesity serve a scavenging action against unbound
circulating lipopolysaccharides with consequent anti-
inflammatory response and improved long-term
outcome.23
Studies of the BMIemortality relationship may suffer
from several sources of bias and confounding which can
explain the U- or J-shaped relationship in some of these
studies. Reverse causality can be present if thin people
are disproportionately more susceptible to disease and
suffer worse health outcomes than those with higher
BMI levels. Another important consideration is potential
overcontrolling by adjustment for cardiovascular risk
factors associated with increased weight.24 25 If BMI
contributes to the development of a risk factor, statistical
adjustment for such risk factors could be misleading with
regard to the contribution of BMI. Besides these meth-
odological and conceptual issues, there are several
potential modifiers of the BMIemortality association.
This association may vary according to variables such as
sex, ethnicity, age and body fat distribution. Another
major problem with BMI is that it is a surrogate,
measuring total body mass. One explanation for a U-
shaped relationship between BMI and mortality is that
calculated BMI measures do not differentiate between
fat and fat-free mass, which have opposite effects on
health and longevity.26
In this study, the impact of differences in optimal
medication, one of the implicated mechanisms of the
obesity paradox, was explored. Strikingly, we did notice
that optimal medical treatment was more common in
the high BMI groups, likely a reflection of the higher
incidence of risk factors in these subgroups. Our study
supports the hypothesis that part of the obesity paradox
may be mediated by the earlier and more complete
secondary preventive medical treatment in the high BMI
groups who present for revascularisation at a younger
age.
Aspirin, statin, b blocker and ACE inhibitor use have
all shown significant reduction in mortality in previous
studies.27 In our study cohort, patients with a higher
BMI were more often on b blocker and ACE inhibitor
treatment when compared with subjects with normal
weight. The positive effect on survival in the long-term of
such drug treatment is an important contributor to the
apparent survival advantage that is observed in patients
with a high BMI. Thus, at least in part, OMTexplains the
obesity paradox. Moreover, our study highlights the
importance of optimising medical treatment and
encouraging compliance even in patients with good
symptom control achieved after percutaneous revascu-
larisation for CAD.
The beneficial effect of OMT in the higher BMI group
may have been influenced by a change in lifestyle. The
change in BMI over time and measures other than OMT
such as exercise and dieting may have contributed to the
improved long-term prognosis in these patients.
Figure 1 KaplaneMeier survival curve for all-cause mortality
in normal weight, overweight and obese patients at 6-year
follow-up.
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Baseline clinical characteristics of patients with a high
BMI suggest that these patients have a higher risk profile
compared with those with normal or low BMI. Clearly,
patients with high BMI undergoing PCI have a more
optimal medical treatment. Whether more active
screening related to the obesity and cardiovascular risk
factors is leading to a more timely and aggressive phar-
macological and/or mechanical intervention in this
population remains to be established.
In an era of stent implantation as a mainstream
treatment for CAD, stent-related factors may also influ-
ence the impact of BMI on clinical outcome. Although
in our study we were not interested in stent-related
outcomes such as stent thrombosis and stent restenosis
with target lesion revascularisation, these two may play
a role in hard end points especially in the long term.
Patients with a high BMI have been shown to have
higher rates of target vessel revascularisation possibly
reflecting more aggressive neointimal hyperplasia in the
stent, progressive disease in the treated vessel or
a combination of the two.14 The coexisting cardiovas-
cular risk factors (hypertension, dyslipidaemia and
particularly diabetes mellitus) in these patients are
thought to play a major role in these mechanisms of
target vessel failure. Stent thrombosis has an even more
direct effect on hard end points since it causes an MI
and sometimes sudden cardiac death even before
presentation. Patients with a high BMI are thought to be
at a higher risk possibly due to suboptimal dosing of
dual antiplatelet treatment.14 Thus, although stent-
related factors can potentially influence the relation of
BMI and outcome, the mechanisms implicated do not
support the obesity paradox that we observe.
The current study has a number of limitations that
need to be highlighted. Data regarding waist circum-
ference and waist/hip ratio that measures abdominal
obesity were not routinely available. A more precise
differentiation between peripheral adiposity and
central compartment adiposity would have served to
support the suggested hypothetical explanation about
the role of a high BMI in prolonging survival in our
patient population. Regarding the detection of our end
points, a number of non-fatal and/or asymptomatic or
silent MIs might have not been reported, especially if
these occurred outside the hospital. Noting that in
patients who have a contraindication to a treatment
option (eg, b blockers), the lack of benefit from this
treatment is not physician induced but determined by
the patient’s condition, which may itself put the latter
in a higher risk category. This will in the future need to
be addressed in a prospective study. Clinical measure-
ment, rather than self-reported height and weight,
would have provided a more accurate BMI data, elimi-
nating any possible bias. OMT was defined according to
patient medication at first time of contact but no
information of duration or compliance of such treat-
ment was available. Objective parameters of lifestyle
modifications and risk factor control would shed light
on the importance of such an intervention on clinical
outcome.
In conclusion, the results of the current study show
that BMI is inversely related to long-term mortality in
patients treated with PCI. Patients with a low BMI are on
suboptimal medical treatment when compared with
those with a high BMI. However, a more optimal medical
treatment in the obese group may explain the improved
outcome in these patients.
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